Jefferies Group restated their buy rating on shares of Celgene Corp. (NASDAQ:CELG) in a report released on Monday morning.

A number of other equities research analysts also recently weighed in on the stock. BTIG Research reissued a buy rating and set a $138.00 price target on shares of Celgene Corp. in a research note on Sunday, August 21st. Vetr downgraded shares of Celgene Corp. from a buy rating to a hold rating and set a $106.06 price target for the company. in a research note on Wednesday, July 6th. Morgan Stanley reissued an equal weight rating and set a $120.00 price target on shares of Celgene Corp. in a research note on Monday, September 12th. Piper Jaffray Cos. reaffirmed an overweight rating and issued a $145.00 target price on shares of Celgene Corp. in a research note on Sunday, October 2nd. Finally, JMP Securities reaffirmed a buy rating and issued a $152.00 target price on shares of Celgene Corp. in a research note on Wednesday, July 6th. Three equities research analysts have rated the stock with a hold rating and twenty-five have assigned a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $136.46.

Analyst Recommendations for Celgene Corp. (NASDAQ:CELG)

Celgene Corp. (NASDAQ:CELG) traded up 0.68% during trading on Monday, reaching $100.32. 228,727 shares of the company were exchanged. The firm has a 50-day moving average of $105.50 and a 200-day moving average of $105.57. Celgene Corp. has a 52-week low of $93.05 and a 52-week high of $128.39. The firm has a market cap of $77.76 billion, a price-to-earnings ratio of 42.40 and a beta of 1.49.

Celgene Corp. (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.39 by $0.05. The business earned $2.74 billion during the quarter, compared to the consensus estimate of $2.70 billion. Celgene Corp. had a net margin of 18.95% and a return on equity of 67.06%. Celgene Corp.’s revenue for the quarter was up 20.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.23 earnings per share. On average, equities analysts forecast that Celgene Corp. will post $5.71 EPS for the current year.

In related news, insider Robert J. Hugin sold 100,000 shares of the company’s stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $110.00, for a total value of $11,000,000.00. Following the transaction, the insider now directly owns 1,022,201 shares in the company, valued at $112,442,110. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Gilla Kaplan sold 9,710 shares of the company’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $106.44, for a total transaction of $1,033,532.40. Following the completion of the transaction, the director now owns 72,142 shares in the company, valued at $7,678,794.48. The disclosure for this sale can be found here. 0.97% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of CELG. Vanguard Group Inc. raised its stake in shares of Celgene Corp. by 0.8% in the second quarter. Vanguard Group Inc. now owns 47,833,717 shares of the biopharmaceutical company’s stock valued at $4,717,840,000 after buying an additional 395,600 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in shares of Celgene Corp. by 0.6% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 20,241,642 shares of the biopharmaceutical company’s stock valued at $1,996,433,000 after buying an additional 117,543 shares in the last quarter. BlackRock Fund Advisors raised its stake in shares of Celgene Corp. by 0.3% in the second quarter. BlackRock Fund Advisors now owns 15,066,831 shares of the biopharmaceutical company’s stock valued at $1,486,042,000 after buying an additional 48,168 shares in the last quarter. Carmignac Gestion raised its stake in shares of Celgene Corp. by 28.1% in the second quarter. Carmignac Gestion now owns 9,708,359 shares of the biopharmaceutical company’s stock valued at $957,535,000 after buying an additional 2,127,659 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in shares of Celgene Corp. by 29.3% in the first quarter. Wellington Management Group LLP now owns 9,105,975 shares of the biopharmaceutical company’s stock valued at $911,417,000 after buying an additional 2,062,585 shares in the last quarter. Institutional investors own 77.70% of the company’s stock.

Celgene Corp. Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Receive News & Stock Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related stocks with our FREE daily email newsletter.